Summit Corporation plc Stock London S.E.
Equities
GB00B02T3K57
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
May. 07 | Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target | MT |
May. 01 | Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024 |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.61B 3.27B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.86% |
Latest transcript on Summit Corporation plc
Managers | Title | Age | Since |
---|---|---|---|
Mahkam Zanganeh
CEO | Chief Executive Officer | 52 | 20-11-10 |
Robert Duggan
CEO | Chief Executive Officer | 79 | 19-11-30 |
Director of Finance/CFO | 46 | 19-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Duggan
CEO | Chief Executive Officer | 79 | 19-11-30 |
Robert Booth
BRD | Director/Board Member | 70 | 22-09-27 |
Director of Finance/CFO | 46 | 19-11-30 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |